Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis

Peritoneal Dialysis International

Volumn 29, Issue 6, 2009, Pages 671-673

  Hassoun, A A ^a   Coomer, R W ^b   Mendez Vigo, L ^c  

^a Alabama Infectious Diseases Center   (United States)

^b Nephrology Consultants   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFTAZIDIME; CHLORAMPHENICOL; CREATINE KINASE; DAPTOMYCIN; DIALYSIS FLUID; GLUCOSE; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; TETRACYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; AGED; ANTIBIOTIC RESISTANCE; ANURIA; ARTICLE; BACTERIAL PERITONITIS; BACTERIUM CULTURE; CASE REPORT; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATINE KINASE BLOOD LEVEL; DIALYSATE; DIALYSIS CATHETER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; ERYTHROCYTE COUNT; HUMAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPHIL COUNT; PERITONEAL FLUID; PRIORITY JOURNAL; REPEATED DRUG DOSE; TURBIDITY; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

EID: 77953495995     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.1177/089686080902900614     Document Type: Article

References (20)

1. Salzer W. Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. Perit Dial Int 2005; 25:313-19.
2. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7:2176-82.
3. Berns JS. Infection with antimicrobial-resistant microorganisms in dialysis patients. Semin Dial 2003; 16:30-7.
4. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002; 62:425-41.
5. Bailey EM, Faber MD, Nafziger DA. Linezolid for treatment of vancomycin-resistant enterococcal peritonitis. Am J Kidney Dis 2001; 38:1-3.
6. Tedla FM, Salifu M, Friedman EA. Successful treatment of vancomycin-resistant enterococcal peritonitis with linezolid in a kidney transplant patient: a case report and review of the literature. Perit Dial Int 2004; 24:70-2.
7. O'Riordan A, Abraham KA, Ho JK, Walshe JJ. Vancomycinresistant peritonitis associated with peritoneal dialysis: a cause for concern. Ir J Med Sci 2002; 171:42-3.
8. Lynn WA, Clutterbuck E, Want S, Markides V, Lacey S, Rogers TR, et al. Treatment of CAPD-peritonitis due to glycopeptide- resistant Enterococcus faecium with quinupristin/ dalfopristin. Lancet 1994; 344:1025-6.
9. Moses J, Brown E, Lynn W, White J, Goldberg LK, Talbot GH. Treatment of vancomycin-resistant Enterococcus faecium CAPD-associated peritonitis with intraperitoneal administration of quinupristin/dalfopristin patients. Presented at the 38th Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 24-27, 1998; San Diego, CA, USA.
10. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44:1062-6.
11. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007; 54:567-71.
12. Cunha BA, Mickail N, Eisenstein L. E. faecalis vancomycinsensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 2007; 36:456-61.
13. Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007; 51:1787-94.
14. Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 2003; 47:3764-7.
15. Troidle L, Kliger AS, Gorban-Brennan N, Fikrig M, Golden M, Finkelstein FO. Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 1996; 50:1368-72.
16. Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996; 156:2579-84.
17. Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/ dalfopristin. Int J Antimicrob Agents 2006; 28:385-8.
18. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005; 49:5166-8.
19. Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51:1656-60.
20. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant grampositive pathogens. Clin Infect Dis 2004; 38:994-1000.